← All trials
NCT03550508
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 21, 2018
- Primary completion
- Aug 30, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai JMT-Bio Inc.Lead sponsor
- CovanceCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- IQVIACollaborator
- KingMed DiagnosticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.